Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares
Reuters
Published May 27, 2020 06:46
PARIS (Reuters) - Sanofi (PA:SASY) will raise over $11 billion (8.93 billion pounds) from the sale of 21.6 million shares in its U.S. partner Regeneron (O:REGN), the French drugmaker said on Wednesday, adding it would use the proceeds for innovation and general growth.
Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership.
Sanofi is selling the Regeneron shares at $515.00 per share - a discount of around 5.5% to Regeneron's closing price of $545.21 on May 26, and raising gross proceeds of $11.1 billion.
Sanofi will continue to own approximately 400,000 shares of Regeneron's common stock.
Sanofi could end up raising $11.7 billion, if the underwriters on the deal exercise their option to buy up a further 1.2 million Regeneron shares.
The collaboration between Sanofi and Regeneron dates back to 2003 and has resulted in five approved treatments to date - including eczema drug Dupixent - with additional candidates in clinical development.
Investment banks Bank of America (NYSE:BAC) Securities, Goldman Sachs (NYSE:GS), Barclays (LON:BARC), BNP Paribas (PA:BNPP), Citigroup (NYSE:C), JP Morgan and Morgan Stanley (NYSE:MS) worked on Sanofi's Regeneron stake sale.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.